Unlocking the potential of nanocarrier-mediated mRNA delivery across diverse biomedical frontiers: A comprehensive review
Int J Biol Macromol. 2024 Apr 12:131139. doi: 10.1016/j.ijbiomac.2024.131139. Online ahead of print.ABSTRACTMessenger RNA (mRNA) has gained marvelous attention for managing and preventing various conditions like cancer, Alzheimer's, infectious diseases, etc. Due to the quick development and success of the COVID-19 mRNA-based vaccines, mRNA has recently grown in prominence. A lot of products are in clinical trials and some are already FDA-approved. However, still improvements in line of optimizing stability and delivery, reducing immunogenicity, increasing efficiency, expanding therapeutic applications, scalability and manufacturing, and long-term safety monitoring are needed. The delivery of mRNA via a nanocarrier system gives a synergistic outcome for managing chronic and complicated conditions. The modified nanocarrier-loaded mRNA has excellent potential as a therapeutic strategy. This emerging platform covers a wide range of diseases, recently, several clinical studies are ongoing and numerous publications are coming out every year. Still, many unexplained physical, biological, and technical problems of mRNA for safer human consumption. These complications were addressed with various nanocarrier formulations. This review systematically summarizes the solved problems and applications of nanocarrier-based mRNA delivery. The modified nanocarrier mRNA meaningfully improved mRNA stability and abridged its immunogenicity issues. Furthermore, several strategies were discussed tha...
Source: International Journal of Biological Macromolecules - Category: Biochemistry Authors: Smita Pawar Prashant Pingale Atul Garkal Riyaz Ali M Osmani Kavita Gajbhiye Madhur Kulkarni Krutika Pardeshi Tejal Mehta Amarjitsing Rajput Source Type: research
More News: Alzheimer's | Biochemistry | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Covid Vaccine | COVID-19 | Infectious Diseases | Nanotechnology | Study | Vaccines